兰德-Economic-Value-of-Advanced-Transfemoral-Prosthetics_51页_1mb

报告摘要

Summary of "Economic Value of Advanced Transfemoral Prosthetics"

Core Content

This research report evaluates the economic value of microprocessor-controlled prosthetic knees (MPKs) compared to non-microprocessor-controlled prosthetic knees (NMPKs) for patients with unilateral transfemoral amputation. The study focuses on the Medicare population, as CMS is the largest payer for prosthetic devices in the U.S. and sets market standards for reimbursement. The findings are intended to inform payers and policymakers regarding the cost-effectiveness of advanced prosthetics and their potential to improve clinical outcomes.

Main Points

Clinical Benefits

Physical Function: MPKs significantly improve physical function compared to NMPKs.
Falls and Mortality: MPKs reduce the incidence of injurious falls and fall-related mortality. Over a ten-year period, for every 100 patients, MPKs lead to 82 fewer major injurious falls, 62 fewer minor injurious falls, and 11 fewer deaths.
Osteoarthritis: MPKs result in 16 fewer incidences of osteoarthritis per 100 patients over a ten-year period.
Quality of Life: MPKs improve quality of life, as measured by quality-adjusted life years (QALYs), by 0.91 per person over ten years.
Life Years: MPKs increase life years by 0.11 per person over the same period.

Economic Benefits

Direct Health Care Costs: MPKs reduce direct health care costs by $3,676 per person per year.
Indirect Costs: They also reduce indirect costs (e.g., caregiving, transportation, work productivity) by $909 per person per year.
Device Acquisition Costs: MPKs increase device acquisition and repair costs by $6,287 per person per year.
Total Cost: The total cost per person over ten years is increased by $1,702 due to MPKs.
Incremental Total Cost: On a per-person basis, the incremental total cost of MPKs is $10,604.
Incremental Cost-Effectiveness Ratio (ICER): The ICER for MPKs is $11,606 per QALY, which is considered good value for money under the standard threshold of $50,000 to $150,000 per QALY.

Key Information

Target Population

The study focuses on Medicare beneficiaries with unilateral transfemoral amputation classified under Functional Classification Levels K3 and K4.
These patients are historically the main users of advanced prosthetics.
In the sensitivity analysis, K1 and K2 amputees were also examined.

Methodology

A simulation model was developed using a Markov cohort model to assess clinical and economic outcomes over a ten-year period.
The model considers fall-related outcomes and osteoarthritis-related outcomes as key factors in converting clinical benefits into economic benefits.
Input parameters were derived from literature reviews, expert consultations, and Medicare claims data.
Costs were adjusted to 2016 U.S. dollars and discounted at a 3% rate.

Cost-Effectiveness Analysis

The ICER is used to evaluate the value for money of MPKs.
The ICER for MPKs is $11,606 per QALY, which is within the accepted range for cost-effectiveness in the U.S.
The economic benefits of MPKs are robust across various sensitivity analyses.

Conclusion

Advanced prosthetics, particularly MPKs, offer substantial clinical benefits for transfemoral amputees, including improved physical function, reduced falls, and lower incidence of osteoarthritis.
These benefits translate into economic savings, particularly in direct and indirect costs, despite higher device acquisition costs.
The study concludes that MPKs provide good value for money and are cost-effective compared to conventional prosthetics.
The findings support the argument that paying for advanced prosthetics is essential to ensure patients can access technologies that improve their quality of life and long-term health outcomes.

Limitations

The study could not quantify the impact of MPKs on low-back pain, depression, obesity, diabetes, and cardiovascular disease due to lack of data.
The model is based on short-term evidence, limiting the ability to make long-term predictions.
The analysis is societal-based, which may not fully reflect the perspective of individual payers or insurers.

Implications

Payers and Policymakers should consider the value-based reimbursement of advanced prosthetics, especially MPKs.
The Prosthetics 2020 Initiative by AOPA is collecting data to support this value-based dialogue.
The absence of a formal ICER threshold in the U.S. allows for a broader interpretation of cost-effectiveness.
Reimbursement restrictions based on functional classification levels may limit patient access to advanced technologies.

Additional Context

Transfemoral amputations are primarily due to peripheral artery disease and diabetes, followed by trauma and cancer.
The payment system for prosthetics is still rooted in unit cost rather than value-based reimbursement.
Cost-cutting pressures on payers may lead to restrictions on advanced prosthetics, potentially limiting patient access to beneficial technologies.
Government payers (e.g., CMS) play a key role in setting reimbursement standards, which influence the market and patient access.